Home/Pipeline/ELIVATE Platform Validation

ELIVATE Platform Validation

Oncology (unspecified)

Pre-clinicalActive

Key Facts

Indication

Oncology (unspecified)

Phase

Pre-clinical

Status

Active

Company

Spirea

About Spirea

Spirea is a private, preclinical-stage biotech leveraging its proprietary ELIVATE linker platform to overcome key limitations in ADC development, such as payload diversity and therapeutic index. The company's technology has demonstrated promising in vivo efficacy and stability in proof-of-concept studies, attracting interest from potential pharmaceutical partners. With a lean, experienced leadership team based in Cambridge, UK, Spirea is positioned to generate value through collaborations and by advancing its own linker-payload candidates toward the clinic.

View full company profile

Therapeutic Areas

Oncology Inflammation Autoimmunity

Other Oncology (unspecified) Drugs

Drug	Company	Phase	Status
Oncology Vaccine Program	CHAIN Biotech	Pre-clinical	Active
Cancer Immunotherapy Nanotherapeutic	Flashpoint Therapeutics	Phase 1	Active
GRWD5769	Greywolf Therapeutics	Phase 1/2	Active
Platform-derived Program(s)	Immuto Scientific	Discovery/Pre-clinical	Active
MBT Oncology Program	Ionic Pharmaceuticals	Pre-clinical	Active
ISB 2301	Ichnos Glenmark Innovation	Preclinical	Active
GRC 65327	Ichnos Glenmark Innovation	Preclinical	Active
Platform-Derived Pipeline	Phinomics	Discovery/Pre-clinical	Active
Lead Small-Molecule Inhibitor	Eris Biotech	Pre-clinical	Active
Orotecan™	Edison Oncology	Phase 1/2a	Active
DDX3 Inhibitor (Oncology)	Lead Discovery Siena	Discovery	Active
Roginolisib (IOA-244)	iOnctura	Phase 2	Active